Skye Bioscience, Inc.

NASDAQ: SKYE · Healthcare · Biotechnology

PublicHQ San Diego, CA · San DiegoCIK 0001516551Reports USD

#1 of 1,418 Healthcare companies by revenue

EA Score

——

FH 27DQ —GM —SS 34

v0.1 · 35/100 weight · pillars only

↑ balance-sheet leverage, filing timeliness · ↓ Piotroski F, workforce scale

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$55.9M

Employees

as of 2026-09-19

Market cap

$7.8M

as of 2026-09-19

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$55.9M-$55.9M2025

Operating income-$58.2M-$58.2M2025

Total assets$28.3M$28.3M2025

Liabilities$8.3M$8.3M2025

Equity$20.0M$20.0M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Skye Bioscience, Inc.’s financial profile?

Skye Bioscience, Inc. earned -$55.9M in FY2025 net income.

Peers · Healthcare

Aprea Therapeutics, Inc.——Advanced Biomed Inc. Common Stock——Quince Therapeutics, Inc.——CNS Pharmaceuticals, Inc.——Apimeds Pharmaceuticals US, Inc——Alzamend Neuro Inc——

Neighbors

San Diego →

QUALCOMM Incorporated$44.3B79B+Realty Income Corporation$5.7B61C Sempra$12.4B63C DexCom, Inc.$4.7B87A ResMed Inc.$5.1B——Illumina, Inc.$4.3B84B+

Key facts

CEOPunit Dhillon

SectorHealthcare

IndustryBiotechnology

HeadquartersSan Diego, CA

ExchangeNASDAQ: SKYE

Employees2

IPO date2015-01-06

Latest filings

8-K2026-09-11 8-K2026-08-24 8-K2026-08-19 8-K2026-08-14 10-Q2026-08-14 8-K2026-06-23 8-K2026-05-29 8-K2026-05-15

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.